10 withdrawn. 10 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Withdrawn 10 |
| Phase 1 | 2 | Withdrawn 2 |
| Phase 3 | 1 | Withdrawn 1 |
Follow COVID: new trials by email Literature Review of COVID trials Research Report on COVID
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients Pentoxifylline, Placebo - COVID | Phase 1 / Phase 2 | Withdrawn | Sadat City University | 2022-11-13 | 2023-01-18 | |
| Niclosamide In Moderate COVID-19 Niclosamide Oral Tablet, Placebo - COVID | Phase 2 | Withdrawn | Entero Therapeutics | 2022-01-20 | 2022-02-21 | |
| Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease Maintenance or reduction of immunosuppression - COVID, Kidney Transplant; Complications | Phase 2 / Phase 3 | Withdrawn | Brigham and Women's Hospital | 2021-05-03 | 2022-05-04 | |
| A Study of Combination Therapies to Treat COVID-19 Infection hydroxychloroquine, Azithromycin, Ritonavir - COVID, COVID-19 | Phase 2 | Withdrawn | ProgenaBiome | 2020-07-01 | 2021-04-08 | |
| Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly Nicotinamide riboside, Placebo - COVID | Phase 2 | Withdrawn | University of Copenhagen | 2020-06-01 | 2022-09-22 | |
| Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19 Sarilumab 200 MG/1.14 ML Subcutaneous Solution, Placebo - COVID, COVID-19 | Phase 2 | Withdrawn | BayCare Health System | 2020-05-07 | 2025-09-29 | |
| Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19 Mesenchymal cells, Standard of care - COVID | Phase 2 | Withdrawn | Hospital Infantil Universitario Niño Jesús, Madrid, Spain | 2020-05-07 | 2021-08-27 | |
| The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations Aspirin 81 mg, Vitamin D - COVID, Vitamin D Deficiency | Phase 2 | Withdrawn | Louisiana State University Health Sciences Center in New Orleans | 2020-05-01 | 2021-12-27 | |
| Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore Hydroxychloroquine - COVID, Coronavirus | Phase 2 | Withdrawn | Montefiore Medical Center | 2020-04-01 | 2020-05-27 | |
| Adoptive Cell Transfer for the Immunotherapy of COVID-19 in Colombia Allogeneic NK transfer - COVID | Phase 1 / Phase 2 | Withdrawn | Universidad Nacional de Colombia | 2020-03-30 | 2021-05-05 |
COVID-19 (4) · Coronavirus Infections (3) · Disseminated Intravascular Coagulation (1) · Hemostatic Disorders (1) · Vitamin D Deficiency (1)
Coronaviridae Infections (4) · Infections (4) · Lung Diseases (4) · Nidovirales Infections (4) · Pneumonia (4) · Pneumonia, Viral (4) · RNA Virus Infections (4) · Respiratory Tract Diseases (4) · Respiratory Tract Infections (4) · Virus Diseases (4) · Avitaminosis (1) · Blood Coagulation Disorders (1) · Cardiovascular Diseases (1) · Coronavirus Infections (1) · Deficiency Diseases (1)
Hydroxychloroquine (2) · Aspirin (1) · Azithromycin (1) · Lopinavir (1) · Maintenance (1) · Niclosamide (1) · Pentoxifylline (1) · Ritonavir (1) · Standard of Care (1) · Vitamin D (1) · nicotinamide-beta-riboside (1) · sarilumab (1)
BayCare Health System (1) · Brigham and Women's Hospital (1) · Entero Therapeutics (1) · Hospital Infantil Universitario Niño Jesús, Madrid, Spain (1) · Louisiana State University Health Sciences Center in New Orleans (1) · Montefiore Medical Center (1) · ProgenaBiome (1) · Sadat City University (1) · Universidad Nacional de Colombia (1) · University of Copenhagen (1)
United States (3) · Colombia (1) · Denmark (1) · Egypt (1) · Spain (1)
Danielle Mauck, BA (1) · Frank H Lau, MD (1) · Jamil Azzi, MD, PhD (1) · Luis Madero, MD (1) · Priya Nori, MD (1) · Sabine Hazan, MD (1) · Thomas Borody, MD, PhD, (1)